Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Braz J Biol ; 83: e276530, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38422267

RESUMEN

A significant public health issue worldwide is metabolic syndrome, a cluster of metabolic illnesses that comprises insulin resistance, obesity, dyslipidemia, hyperglycemia, and hypertension. The creation of natural treatments and preventions for metabolic syndrome is crucial. Chitosan, along with its nanoformulations, is an oligomer of chitin, the second-most prevalent polymer in nature, which is created via deacetylation. Due to its plentiful biological actions in recent years, chitosan and its nanoformulations have drawn much interest. Recently, the chitosan nanoparticle-based delivery of CRISPR-Cas9 has been applied in treating metabolic syndromes. The benefits of chitosan and its nanoformulations on insulin resistance, obesity, diabetes mellitus, dyslipidemia, hyperglycemia, and hypertension will be outlined in the present review, highlighting potential mechanisms for the avoidance and medication of the metabolic syndromes by chitosan and its nanoformulations.


Asunto(s)
Quitosano , Dislipidemias , Hiperglucemia , Hipertensión , Resistencia a la Insulina , Síndrome Metabólico , Humanos , Síndrome Metabólico/tratamiento farmacológico , Quitosano/uso terapéutico , Obesidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...